Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions
Completed · Not applicable
Conditions studied: Short Term Treatment of Insomnia
In brief
The objective of this study was to show the bioequivalence of a Roxane Laboratories' Zaleplon Capsules, 10 mg, to Sonata ® Capsules, 10 mg (Jones Pharma) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design
Key facts
- Study ID
- NCT00694187
- Run by
- Roxane Laboratories
- People needed
- 39
- Starts
- 2004-01-01
- Expected to finish
- 2004-02-01
- Last updated by the study team
- 2018-01-23
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
You may not qualify if…
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Zaleplon or any comparable or similar product.
Where it is running
- Novum Pharmaceutical Research Services — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.